Oncotarget.net features press releases on the latest oncology research, as well as interviews from the distinguished network of authors who continue to publish their research with Oncotarget.

Tag: drug resisance

Figure 1: Representative histopathologic slides stained with hematoxylin and eosin of thyroid cancer from well-differentiated to dedifferentiated states.

Oncotarget

Genetic Alterations in Thyroid Cancer Mediate Resistance to BRAF Inhibition and Anaplastic Transformation

January 29, 2024

“An improved understanding of the molecular basis of thyroid cancer has led to the development of new targeted agents.” BUFFALO, NY- January 29, 2024 – A new research perspective was… read more

Oncotarget

Management of Refractory or Relapsed Classic Hodgkin Lymphoma in Brazil

December 20, 2023

“The management of patients with refractory or relapsed CHL in the Brazilian healthcare setting is constrained [...]” BUFFALO, NY- December 20, 2023 – A new review paper was published in… read more

Oncotarget

Cytostatic Persister Cancer Cells: Therapeutic Opportunities and Challenges

December 13, 2023

“[...] we anticipate that heterogeneous persister populations are inevitable in [cancer] treatment.” BUFFALO, NY- December 13, 2023 – A new editorial paper was published in Oncotarget's Volume 14 on December… read more

Oncotarget

Suppression of Cancer Stemness and Drug Resistance via BRAF/EGFR/MEK Inhibition in Colorectal Cancer Cells

October 11, 2023

“[...] our approach enables mechanistic studies of drug resistance with 3D cultures of primary cancer cells to develop and test treatments that suppress cancer [...].” BUFFALO, NY- October 11, 2023… read more